Publication:
Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Issued Date

2021-01-01

Resource Type

Article

ISSN

10984275
00314005

DOI

10.1542/PEDS.2019-4035

Other identifier(s)

2-s2.0-85099326316

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Pediatrics. Vol.147, No.1 (2021)

Suggested Citation

Jacob Bornstein, Surita Roux, Lone Kjeld Petersen, Li Min Huang, Simon R. Dobson, Punnee Pitisuttithum, Javier Diez-Domingo, Andrea Schilling, Hany Ariffin, Richard Tytus, Richard Rupp, Shelly Senders, Eli Engel, Daron Ferris, Yae Jean Kim, Young Tae Kim, Zafer Kurugol, Oliver Bautista, Katrina M. Nolan, Sandhya Sankaranarayanan, Alfred Saah, Alain Luxembourg Three-year follow-up of 2-dose versus 3-dose HPV vaccine. Pediatrics. Vol.147, No.1 (2021). doi:10.1542/PEDS.2019-4035 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78854

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Author(s)

Jacob Bornstein
 Surita Roux
 Lone Kjeld Petersen
 Li Min Huang
 Simon R. Dobson
 Punnee Pitisuttithum
 Javier Diez-Domingo
 Andrea Schilling
 Hany Ariffin
 Richard Tytus
 Richard Rupp
 Shelly Senders
 Eli Engel
 Daron Ferris
 Yae Jean Kim
 Young Tae Kim
 Zafer Kurugol
 Oliver Bautista
 Katrina M. Nolan
 Sandhya Sankaranarayanan
 Alfred Saah
 Alain Luxembourg

Other Contributor(s)

National Taiwan University Hospital
 Medical College of Georgia
 Ege Üniversitesi
 Yonsei University College of Medicine
 Odense Universitetshospital
 UT Medical Branch at Galveston
 University of Malaya Medical Centre
 Mahidol University
 The University of British Columbia
 Merck & Co., Inc.
 Sungkyunkwan University
 Bar-Ilan University
 Clinica Alemana
 Bayview Research Group
 Synexus Clinical Research SA
 Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
 Senders Pediatrics
 Hamilton Medical Research Group

Abstract

BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/78854

Collections

Scopus 2021